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IntroductIon
Barrett’s esophagus (BE) is a premalignant 
condition of the esophagus, defined as displacement 
of the normal stratified squamous epithelium by 
specialized columnar lined epithelium. It is a common 
condition, affecting up to 2 per cent of the adult 
population. BE often arises as a consequence of 
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AbstrAct
Genetic changes involved in the metaplastic progression from squamous 
esophageal mucosa toward Barrett’s metaplasia and adenocarcinoma are almost 
unknown. Several evidences suggest that some miRNAs are differentially expressed 
in Barrett’s esophagus (BE) and esophageal adenocarcinoma. Among these, miR-143, 
miR-145, miR-194, miR-203, miR-205, miR-215 appear to have a key role in metaplasia 
and neoplastic progression. The aim of this study was to analyze deregulated miRNAs 
in serum and esophageal mucosal tissue biopsies to identify new biomarkers that could 
be associated with different stages of esophageal disease. Esophageal mucosal tissue 
biopsies and blood samples were collected and analyzed for BE diagnosis. Quantitative 
Real-time PCR was used to compare miRNA expression levels in serum and 60 disease/
normal-paired tissues from 30 patients diagnosed with esophagitis, columnar-lined 
oesophagus (CLO) or BE. MiRNA expression analysis showed that miR-143, miR-145, 
miR-194 and miR-215 levels were significantly higher, while miR-203 and miR-205 
were lower in BE tissues compared with their corresponding normal tissues. Esophageal 
mucosa analysis of patients with CLO and esophagitis showed that these miRNAs were 
similarly deregulated but to a lesser extent keeping the same trend and CLO appeared 
as intermediate step between esophagitis and BE. Analysis on circulating miRNA levels 
confirmed that miR-194 and miR-215 were significantly upregulated in both BE and 
CLO compared to esophagitis, while miR-143 was significantly upregulated only in 
the Barrett group. These findings suggest that miRNAs may be involved in neoplastic/
metaplastic progression and miRNA analysis might be useful for progression risk 
prediction as well as for monitoring of BE/CLO patients.
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mucosal injury from chronic gastro-esophageal reflux 
disease (GERD) [1–3].
Although, over the years, several authors have 
tried to better define this condition does not exist today 
a universally accepted definition of BE. The American 
College of Gastroenterology (ACG) reported that BE “is 
confirmed to have intestinal metaplasia by biopsy of the 
tubular esophagus” [4]. However, the requirement for 
identification of intestinal metaplasia on biopsy is not 
demanded by the British Society of Gastroenterology 
(BSG) [5].
It is broadly accepted that metaplasia with goblet 
cells is associated with premalignant dysplasia and risk 
of progression to esophageal adenocarcinoma (EAC) 
[6]. Intestinal metaplasia is essential for the diagnosis 
of Barrett’s esophagus and enrolment into endoscopic 
surveillance programs. Simultaneously, columnar metaplasia 
in the esophagus without intestinal specialized epithelium is 
defined as “Columnar-lined oesophagus” (CLO) but whether 
it is a criterion for inclusion in standardized endoscopic 
surveillance programs is still a matter for debate [4, 7]. 
Our previous study demonstrated that CLO 
differs from the true oxyntic-gastric mucosa for positive 
cytokeratin 7 immunostaining indicative of a reflux damage 
[8]. In addition, Agnese et al. [9] reported that BE and CLO 
samples were positive for the Aurora kinase A transcript 
compared to controls, consistently with its overexpression 
reported in many types of human malignancies [10, 11], 
but there were no statistically significant quantitative 
differences in Aurora-A messenger RNA expression 
between CLO and BE and p53-positive immunostaining.
It is still unclear how the squamous epithelium 
undergoes its initial metaplastic transformation to a columnar 
mucosa, and whether CLO is precursor of intestinal 
metaplasia. Metaplastic transformation appears to be the key 
event leading to an unstable epithelium which is capable of 
neoplastic progression and it is unlikely that the presence 
of goblet cells can be sufficient for malignant risk to EAC 
[12–14].
In recent years, the role of microRNAs (miRNAs) 
as potential and ideal biomarkers has been investigated 
and developed. MiRNA is a new class of  small non-
coding  RNA molecules, about 20–25 nucleotides in length, 
encoded by cell endogenous genes which have been shown 
to negatively regulate more than 30% of the coding genes in 
the human genome via translational repression or mRNA 
degradation [15–17]. Changes in miRNA expression could 
be important in the development of BE and its progression. 
Among them, miR-143, miR-145, miR-194, miR-203, miR-
205, miR-215 appear to have a key role in the metaplasia 
and in neoplastic progression [18–20].
MiR-143, miR-145 and miR-215 are downregulated 
in EAC. Similar results have been found in colon, gastric 
and lung cancer [21–23]. These findings suggest that we 
may define miR-143, miR-145 and miR-215 as tumor 
suppressors, with loss of expression contributing to the 
development of esophageal adenocarcinoma. In addition, it 
has been reported that miR-194 is upregulated in BE and 
EAC. An increased miRNA-194 expression has been linked 
to intestinal epithelium differentiation [24]. Similarly, miR-
203 and miR-205 were reported highly expressed in normal 
squamous epithelium compared with columnar epithelia 
[25].
In addition, several studies have shown that it is 
possible to evaluate the expression of cell-free miRNAs 
in different body fluids. Recently, Bus and colleagues 
performed miRNA expression profiling using plasma from 
6 controls, 8 patients with BE and 8 with EAC showing that 
circulating miRNAs are differentially expressed in BE and 
EAC [26].
The aim of this study was to analyze deregulated 
miRNAs in serum and esophageal mucosal tissue biopsies 
from subjects undergoing upper gastrointestinal endoscopy 
in order to identify some biomarkers that could be 
associated with different stages of esophageal disease.
results
Patients
Esophageal mucosal tissue biopsies and blood 
samples were collected from individuals undergoing upper 
gastrointestinal endoscopy at Department of Surgical, 
Oncological and Oral Sciences, University of Palermo.
The 30 patients enrolled in the study, 9 male and 21 
female, showed a mean age of 52 years. All patients were 
Caucasian and 9 of them had a body-mass index higher 
than 30. Only six patients were regular smokers at the time 
of interview. Twelve patients were already included in a 
program of endoscopic surveillance, while 23 had frequent 
reflux symptoms at the time of endoscopic evaluation 
(Table 1).
The histological examination performed on serial 
sections stained with H & E and Alcian-PAS showed the 
presence of Barrett’s esophagus in 8 patients, CLO in 12 
and distal esophagitis (erosive and non) in 10 patients 
(Figure 1A–1C) (Table 1).
micrornA expression in esophageal mucosal 
tissue biopsies
In this study, the expression of miR-143, miR-145, 
miR-194, miR-203, miR-205 and miR-215 was analyzed in 
60 disease/normal-paired FFPE tissue samples used before 
for histological assessment, from 30 patients diagnosed 
with esophagitis, CLO or BE (Table 2). 
The expression miR-143, miR-145 was found 
upregulated compared to normal tissue of the surrounding 
esophagus, with a progressive increase during progression 
from esophagitis to CLO without intestinal metaplasia and 
then BE with the presence of goblet cells (median fold 
change > 0.5). The expression of miR-203, miR-205 was 
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significantly downregulated in the group of patients with 
intestinal metaplasia and to lesser extent in patients with 
CLO ( median fold change < −0.5) while did not change 
in patients with esophagitis (median fold change > −0.5). 
Conversely, miR-194 and miR-215 were upregulated 
in patients with BE and with a lesser degree in patients 
with CLO (median fold change > 0.5) while the expression 
levels of these miRNAs did not change in patients with 
esophagitis (median fold change < 0.5).
Using the Mann Whitney test there were statistically 
significant differences between the Esophagitis and Barrett 
groups as regard the expression of all examined miRNAs 
(Barrett vs Esophagitis). In addition, miR-143, miR-145, 
miR-194 and miR-215 showed statistically significant 
differences in expression levels between CLO and Barrett 
groups (Barrett vs CLO) and between CLO and Esophagitis 
groups (CLO vs Esophagitis) (Figure 2). 
Subsequently, Kruskal-Wallis test that allows the 
comparison of more than 2 groups, in the present case 
Barrett vs CLO vs Esophagitis was used. Interestingly, 
all analyzed miRNAs showed statistically significant 
differences between the three groups (Figure 3).
micrornA expression in serum samples
Finally miR-143, miR-145, miR-194, miR-203, 
miR-205, miR-215 serum levels were analyzed in the same 
patients in order to investigate if there is a relationship 
with the expression levels in the tissue samples (Figure 4).
Consistent with data from the tissue samples, the 
expression levels of circulating miR-143, miR-194 and 
miR-215 were found upregulated in serum of  patients 
with BE  compared to patients with CLO and esophagitis. 
In addition, the miR-194 and miR-215 expression levels 
were significantly upregulated in the serum of patients with 
CLO compared to patients with esophagitis reinforcing the 
hypothesis that CLO is an intermediate step between BE 
and esophagitis. 
table 1: Patient characteristics
Histological diagnosis
barrett’esophagus clo esophagitis
sex
Male 9 5 2 2
Female 21 3 10 8
Age
< 50 16 0 6 7
> 50 14 8 6 3
race
White 30 8 12 10
Black 0 0 0 0
body-mass index
Obesity 9 1 5 3
Normal weight 21 7 7 7
smoking
Smokers 6 2 3 1
Non-smokers 24 6 9 9
Reflux symptoms 
Frequent 23 6 11 6
Infrequent 7 2 1 4
endoscopic surveillance 
Yes 12 4 5 3
No 18 4 7 7
Figure 1: (A) Distal esophagitis. (b) Non-intestinalized columnar-lined oesophagus (CLO) without acidic mucins and negative for Alcian 
blue stain; (c) Columnar-lined esophageal mucosa with intestinal metaplasia (Barrett’s esophagus) characterized by goblet cells appearing 
as Alcian blue positive cells for the presence of acidic mucins. (A,B,C) Alcian-PAS staining, original magnification 100×.
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However, the expression of serum miR-145, miR-203 
and miR-205 not change between the different groups. 
dIscussIon
MiRNAs are involved in the regulation of a wide 
range of biological processes, such mechanisms of 
embryonic development, cell differentiation, apoptosis, 
cell growth control and regulation of metabolic processes 
[27−30]. Changes in miRNAs could be important in the 
development of BE and its progression [18, 31, 32]. Among 
them, miR-143, miR-145, miR-194, miR-203, miR-205, 
miR-215 appear to have a key role in the metaplasia and 
in neoplastic progression. In particular, numerous studies 
reported the downregulation of miR-143, miR-145, 
miR-203, miR-205 and miR-215 in EAC [18, 33]. 
However, few studies have been performed on lesions 
preceding the adenocarcinoma and in particular on the 
miRNA expression in the different types of columnar 
mucosa and esophagitis. 
table 2: Mean, median and standard deviation of mir-143, mir-145, mir-194, mir-203, mir-
205 and mir-215 relative expression values in relation to the histologic phenotype (barrett, clo, 
esophagitis)(log scale)
mirnA Id
barrett (n = 8) clo (n = 12) esophagitis (n = 10)
mean median sd mean median sd mean median sd
mir-143 4.55 4.32 1.69 3.13 3.31 1.10 0.68 0.55 1.17
mir-145 4.79 4.59 1.20 3.27 3.34 1.20 0.72 0.57 0.75
mir-194 7.99 8.27 1.31 5.30 6.25 3.16 0.56 0.24 1.74
mir-203 −3.92 −4.32 1.41 −3.09 −3.13 2.59 −0.91 −0.49 1.28
mir-205 −5.62 −5.43 2.97 −4.60 −1.96 5.25 −0.39 −0.27 0.66
mir-215 8.23 8.56 2.33 5.06 5.56 2.53 0.14 −0.20 1.86
Figure 2: relative mir-143, mir-145, mir-194, mir-203, mir-205, mir-215 expression levels (logarithmic scale). 
Relative expression levels are represented as mean values with SD (standard deviation) for each group. Each sample was normalized using 
the corresponding normal counterpart (10 cm above the Z-line). Normal tissue expression levels were set as 0. Differences in miRNA 
expression between the different groups were considered significant when the p value was under 0.05 (*) and 0.001(**).
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Recent evidence showed that miR-203 and miR-205 
are expressed at higher levels in squamous mucosa, and 
miR-143, miR-145, miR-194 and miR-215 are expressed 
at higher levels in BE [18].
In this study,  it has been shown how the miR-143, 
miR-145, miR-194, miR-203, miR-205 and miR-215 
are differentially expressed in esophageal mucosa with 
esophagitis, CLO or BE compared to the adjacent normal 
tissues of the surrounding esophagus.  Furthermore, it has 
been described how these deregulations change between the 
different groups of patients.
Here, the upregulation of miR-143 and miR-145 was 
found both in esophagitis than in columnar metaplasia, both 
gastric and intestinal with a progressive increase during 
progression from esophagitis to CLO without intestinal 
metaplasia and then BE with the presence of goblet cells. 
Similarly, miR-215 was upregulated in patients with BE and 
with a lesser degree in patients with CLO. These findings 
are in line with the role that these three miRNAs play in 
the DNA damage repair process caused by the perpetuation 
of gastroesophageal reflux. In particular, miR-143, miR-145 
and miR-215 are considered tumor suppressors, 
downregulated in EAC probably due to additional molecular 
alterations that occur during carcinogenesis, such as loss 
of p53 homozygosity with consequent alteration of the 
functionality and ability that p53 exerts on the regulation of 
these three miRNAs [23, 34−36]. In addition, the analysis 
of miR-145, most upregulated in BE compared to CLO, 
is consistent with its role in the differentiation towards the 
intestinal metaplasia via the feedback circuit with BMP-4, 
which is reported to be overexpressed in BE [37]. In the 
present study, miR-145 is also up-regulated in the CLO, 
although to a lesser extent. In fact, in CLO the intestinal 
metaplasia is not yet manifested phenotypically, although 
the presence of some Alcian blue positive cells and the 
focal positivity for CDX2 suggest that the CLO is an early 
stage of the same intestinal metaplasia. This hypothesis is 
confirmed by studying trends in the different groups of all 
analyzed miRNAs. In fact, although some miRNAs did not 
show a statistically significant difference in the expression 
levels between CLO and Barrett and between CLO and 
Esophagitis, there was a clear trend up or downregulation, 
under which the CLO appeared as intermediate step between 
Esophagitis and BE.
miR-194 was found upregulated in patients with BE 
and with a lesser degree in patients with CLO while the 
expression levels of this miRNA did not change in patients 
with esophagitis. An increased miRNA-194 expression has 
Figure 3: differences in micrornA expression between different groups. Kruskal-Wallis test was used for comparisons of 
differences in the expression levels in the 3 groups. All the analyzed miRNAs showed statistically significant differences in the expression 
levels between the groups.
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been linked to intestinal epithelium differentiation [24] but 
this miRNA does not seem to act like oncomiR or anti-
oncomiR and therefore probably the upregulation of miR-
194 is maintained even in EAC [18, 38, 39].
The miR-203 was progressively downregulated 
during progression from esophagitis to CLO and then BE. 
This downregulation, also found in adenocarcinoma could 
be related to the loss of native squamous phenotype and 
emerging columnar morphology [33]. In particular, it has 
been reported that when miR-203 is lost, p63, a target of 
miR-203, is continuously expressed in other differentiated 
suprabasal cells and stimulates their division [40, 41].
The expression of miR-205 was significantly 
downregulated in the group of patients with BE and to lesser 
extent in patients with CLO. Previous studies have shown 
that miR-205 is downregulated EAC [18, 25]. The absence 
of a statistically significant difference in the expression 
levels of miR-205 between esophagitis and CLO could 
indicate that at least for this miRNA there is no significant 
effect in tumor progression, while the downregulation 
observed in BE could be in line with the higher risk of 
neoplastic progression recognized for this lesion.
To date, there are few studies on circulating 
microRNAs both in BE and EAC. Identifying the 
correlation between circulating miRNAs and tissue 
miRNAs would support the hypothesis that circulating 
miRNAs can serve as ideal biomarkers for various 
diseases. Here, we reported that miR-194 and miR-215 
could be potential non-invasive biomarkers for Barrett’s 
esophagus and probably for CLO. Indeed, consistent with 
data from the tissue samples, miR-194 and miR-215 were 
significantly upregulated in BE and CLO compared to 
esophagitis group, and their expressions appear to increase 
progressively in serum from esophagitis to CLO and finally 
Figure 4: serum mir-143, mir-145, mir-194, mir-203, mir-205, mir-215 expression levels (2−ΔCT) in barrett, clo 
and esophagitis groups. Differences in miRNA expression between the different groups were considered significant when the p value 
was under 0.05 (*).
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to BE. In addition, the expression of circulating miR-143 
was found significantly upregulated only in the BE. Our 
findings suggest that these miRNAs could be used as non-
invasive biomarkers of BE and CLO in order to monitor 
patients at higher risk of developing EAC. 
The results of this study confirm that the columnar 
metaplasia, both gastric-type and intestinal-type, although 
it is a higher risk for neoplastic progression, still does not 
have all the molecular alterations that characterize EAC. 
Further studies in order to re-analyze the expression of these 
miRNAs in subjects with different degrees of dysplasia and 
adenocarcinoma will be needed. In our case, considering 
that it was a prospective study and the low incidence of 
these cancers, it has not been possible to analyze tissues 
with this phenotype.
The current endoscopic surveillance programs 
have several limitations. The endoscopic procedure can 
be uncomfortable for patients. Many dysplastic or early 
neoplastic lesions are not visible to the naked eye, resulting 
in missed lesions on biopsy. Most of patients with BE will 
not develop EAC, but continue to undergo the anxiety often 
associated with repeated endoscopies. The most promising 
improvement of surveillance programs would be risk 
stratification of patients using a variety of markers, such as 
clinical risk factors, and biomarkers as miRNAs could have 
all these features and capabilities.
The upregulation of miR-143, miR-145 and miR-215, 
as reported in this study, could be considered an increase 
of the protective mechanism, at least in the earliest stages 
of the metaplastic process. Since miR-143, miR-145 and 
miR-215 are downregulated in EAC, further studies could 
evaluate the expression of these microRNAs in the stages 
of the metaplastic process in which there is the appearance 
of dysplasia. Similarly, miR-194, that we found more 
upregulated in BE compared to CLO, could represent an 
early biomarker for intestinal metaplasia, currently with a 
greatest risk for progression to EAC.
In conclusion, these findings suggest that miRNAs 
may be involved in the neoplastic/metaplastic progression 
and miRNA analysis might be useful for progression risk 
prediction as well as for monitoring of BE/CLO patients. 
Future efforts should focus on the similarities and 
differences in the expression of miRNAs between the 
columnar metaplasia and normal esophageal epithelium, 
evaluating a greater number of patients with chronic 
gastroesophageal reflux showing macroscopic changes at 
the level of the gastroesophageal junction during endoscopic 
assessment.
MAterIAls And MetHods
sample collection
Esophageal mucosal tissue biopsies and blood 
samples were collected from individuals undergoing 
upper gastrointestinal endoscopy. All participants were 
provided with complete information about the study and all 
procedures performed were in accordance with the ethical 
standards of the institutional and/or national research 
committee and with the 1964 Helsinki declaration and its 
later amendments or comparable ethical standards. 
A total of 30 pairs of disease tissues and adjacent 
normal tissues of the surrounding esophagus from 30 patients 
were obtained prospectively from Department of Surgical, 
Oncological and Oral Sciences, University of Palermo.
For each patient, the biopsies were collected 
in neutral buffered formalin at pH 7 for histological 
evaluation as follows:
-  biopsies of healthy esophageal mucosa, taken at 10 
cm above the Z-line
-  biopsies with endoscopic evidence of esophagitis 
and/or columnar metaplasia, collected from the 
esophageal squamous mucosa 2–3 cm above the 
gastro-esophageal junction.
Blood samples from the same patients were drawn 
at the time of obtaining peripheral vein access for the 
endoscopic procedure. Serum samples were isolated by 
centrifugation (3000 rcf) from 5 ml of total blood and 
stored at −80°C until use.
Histopathology
The clinical diagnosis was confirmed by 
histopathology, with Barrett’s esophagus defined as the 
presence of columnar-lined esophageal mucosa with 
intestinal metaplasia within the distal esophageal segment. 
Biopsy samples were formalin-fixed, paraffin-
embedded sections (3 μm thick) were obtained and stained 
with Hematoxylin and Eosin (H & E) followed by special 
stains for mucins Alcian blue pH 2.5/periodic acid–Schiff 
diastase staining (Alcian-PAS). All the specimens were 
reviewed by two different experienced gastrointestinal 
pathologists before miRNA extraction.
Metaplastic lesions were classified as non-
intestinalized or intestinalized based on the presence 
of goblet cells, assessed by Alcian-PAS staining. Non-
intestinalized metaplastic lesions were described here as 
“columnar lined oesophagus” (CLO).
First, histopathology from the formalin-fixed portion 
of these tissues was used before miRNA expression 
analysis, to confirm that the samples consisted of the 
appropriate epithelium. After, the remaining formalin-
fixed, paraffin-embedded tissue was used for gene 
expression analysis.
MirnA isolation
Formalin-fixed, paraffin-embedded biopsy samples 
were deparaffinized and underwent total RNA and miRNA 
extraction using miRNeasy FFPE Kit (Qiagen Inc., Valencia, 
CA, USA) according to the manufacturer’s instructions. 
miRNA yield was determined through a NanoDrop ND-
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1000 spectrophotometer (CELBIO), and the quality assessed 
by agarose gel electrophoresis.
Total miRNAs were isolated from thawed serum 
samples using NucleoSpin miRNA Plasma kit (Macherey-
Nagel, Düren, Germany). Total miRNAs were extracted 
from 300 μL, 600 μL or 900 μL of serum and further eluted 
in 30 μL of nuclease-free water. The miRNA concentration 
and quality were assessed with the Bioanalyzer 2100 
(Agilent Technologies, CA) using the Agilent Small RNA 
Analysis kit (Agilent, CA).
reverse transcription (rt) and quantitative 
real-time polymerase chain reaction (qrt-Pcr)
Quantitative real-time PCR was used to measure 
miRNA expression levels in 60 disease/normal-paired 
esophageal mucosal biopsies and 30 serum samples from 
the same patients. Ten nanograms of total RNA were reverse 
transcribed using TaqMan MicroRNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA, USA) according 
to manufacturer’s instructions. RT reactions contained 
10 ng of RNA sample, 100 nmol/l stem–loop RT primer, 
100 mmol/l deoxynucleoside 5-triphosphates, 50 units/μl 
MultiscribeTM RT, 20 units/μl RNase inhibitor, 1·5 μl 10 × 
RT buffer (all from Applied Biosystems) and nuclease-free 
water. The 15-μl reactions were incubated in a Thermocycler 
(Eppendorf, North Ryde, New South Wales, Australia) for 
30 min at 16°C, 30 min at 42°C, 5 min at 85°C and then 
held at 4°C.
The following Applied Biosystems assays were used 
for TaqMan analysis: hsa-miR-203 (Assay ID 000507); 
hsa-miR-205 (Assay ID 000509); hsa-miR-143 (Assay ID 
002249); hsa-miR-145 (Assay ID 002278); hsa-miR-194 
(Assay ID 000493); hsa-miR-215 (Assay ID 000518). 
The reactions were incubated in a 96-well plate at 95°C 
for 10 min followed by 40 cycles of 95°C for 15 s and 
60°C for 1 min. The quantitative PCR was performed on 
an Applied Biosystems 7900HT fast RT-PCR system, and 
data were collected and analyzed using ABI SDS version 
2.3. Triplicate reactions were performed on all samples. To 
normalize qRT-PCR reactions, parallel reactions were run 
on each sample for Small RNA U48 (Assay ID 001006), 
for both tissue and serum samples. Changes in miRNA 
expression levels were determined using a comparative CT 
method.
statistical analysis
Data processing and analysis were conducted using 
tools from Microsoft Excel and Prism GraphPad software 
(GraphPad Software, CA). Comparisons in the different 
miRNA expression levels between groups were performed 
using Mann Whitney or Kruskal-Wallis test depending on 
the distribution of the data. Only miRNAs with a cut-off 
of cycle threshold (Ct) < 31 were considered in tissue 
samples while no cut-off was applied in the case of serum 
since in this fluid the quantities of starting materials are 
much lower. Differences in miRNA expression were 
considered significant when the P value was under 0.05 
(*) and 0.001(**).
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